Equities research analysts expect that Omeros Co. (NASDAQ:OMER) will announce sales of $2.59 million for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Omeros’ earnings. The lowest sales estimate is $1.97 million and the highest is $3.20 million. Omeros posted sales of $17.15 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 84.9%. The company is scheduled to issue its next earnings report on Tuesday, August 14th.
On average, analysts expect that Omeros will report full-year sales of $18.22 million for the current year, with estimates ranging from $9.63 million to $26.80 million. For the next financial year, analysts expect that the firm will report sales of $99.08 million per share, with estimates ranging from $27.46 million to $170.70 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that that provide coverage for Omeros.
Omeros (NASDAQ:OMER) last posted its quarterly earnings results on Thursday, May 10th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.05). The business had revenue of $1.59 million for the quarter, compared to the consensus estimate of $2.08 million. During the same period in the previous year, the company earned ($0.34) earnings per share. The company’s revenue was down 87.0% compared to the same quarter last year.
Several equities analysts have recently weighed in on the stock. BidaskClub raised shares of Omeros from a “strong sell” rating to a “sell” rating in a report on Friday, March 23rd. HC Wainwright set a $30.00 target price on shares of Omeros and gave the company a “buy” rating in a report on Monday, March 5th. ValuEngine raised shares of Omeros from a “sell” rating to a “hold” rating in a report on Friday, March 23rd. Zacks Investment Research raised shares of Omeros from a “sell” rating to a “hold” rating in a report on Wednesday. Finally, Maxim Group set a $24.00 target price on shares of Omeros and gave the company a “buy” rating in a report on Friday, March 2nd. Seven analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $26.00.
In other news, VP Michael A. Jacobsen sold 23,792 shares of Omeros stock in a transaction that occurred on Tuesday, May 15th. The shares were sold at an average price of $23.80, for a total transaction of $566,249.60. Following the completion of the transaction, the vice president now directly owns 19,480 shares of the company’s stock, valued at approximately $463,624. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 12.10% of the stock is owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. grew its stake in Omeros by 0.9% in the 1st quarter. BlackRock Inc. now owns 3,965,410 shares of the biopharmaceutical company’s stock valued at $44,294,000 after acquiring an additional 34,832 shares during the period. Capital Analysts LLC grew its stake in Omeros by 885.6% in the 4th quarter. Capital Analysts LLC now owns 590,849 shares of the biopharmaceutical company’s stock valued at $36,125,000 after acquiring an additional 530,899 shares during the period. UBS Group AG grew its stake in Omeros by 9.4% in the 1st quarter. UBS Group AG now owns 397,583 shares of the biopharmaceutical company’s stock valued at $4,441,000 after acquiring an additional 34,290 shares during the period. Geode Capital Management LLC grew its stake in Omeros by 3.1% in the 4th quarter. Geode Capital Management LLC now owns 391,649 shares of the biopharmaceutical company’s stock valued at $7,609,000 after acquiring an additional 11,667 shares during the period. Finally, Stifel Financial Corp grew its stake in Omeros by 1.9% in the 1st quarter. Stifel Financial Corp now owns 348,726 shares of the biopharmaceutical company’s stock valued at $3,902,000 after acquiring an additional 6,534 shares during the period. 46.09% of the stock is currently owned by hedge funds and other institutional investors.
Omeros traded up $0.29, reaching $19.69, during trading on Monday, according to MarketBeat Ratings. 476,466 shares of the company’s stock were exchanged, compared to its average volume of 1,247,520. Omeros has a 1 year low of $8.36 and a 1 year high of $27.09. The company has a current ratio of 3.19, a quick ratio of 3.18 and a debt-to-equity ratio of -2.91. The firm has a market capitalization of $893.90 million, a PE ratio of -24.92 and a beta of 3.63.
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.